mhurhangee/ep-ind-claims huggingface dataset:
Process for producing flexible PUR foams having a DIN EN ISO 3386-1-98 apparent density in the range of ≥ 63 kg/m 3 toy 83 kg/m 3 and a DIN EN ISO 2439-1-2009 hysteresis of ≤ 16 by reaction of component A containing A1 at least one polyether polyol having a functionality of 2 to 6, a DIN 53240 hydroxyl number (OH number) of 9 to 112 mg KOH/g, an ethylene oxide fraction of 5 to 40 wt% (based on the sum total of alkylene oxides used), A2 water and/or physical blowing agents, A3 optionally isocyanate-reactive hydrogen compounds having an OH number of 140 mg KOH/g to 1800 mg KOH/g, A4 auxiliary and added-substance materials such as a) catalysts, b) surface-active added-substance materials, and c) pigments or flame retardants, wherein component A is free of polyricinoleic esters, with component B containing a mixture of di- and polyisocyanates of the diphenylmethane series, optionally one or more polyether polyols having a functionality of 2 to 8, preferably of 2 to 6, a DIN 53240 OH number of ≥ 9 mg KOH/g to ≤ 56 mg KOH/g, wherein the ratio of 4,4'-MDI to 2,4'-MDI is between 1.6 and 2.7 and total monomer content is 75 to 85 wt%, based on the sum total of isocyanates used, wherein the flexible PUR foam is produced at an isocyanate index of 75 to 110. A1 at least one polyether polyol having a functionality of 2 to 6, a DIN 53240 hydroxyl number (OH number) of 9 to 112 mg KOH/g, an ethylene oxide fraction of 5 to 40 wt% (based on the sum total of alkylene oxides used), A2 water and/or physical blowing agents, A3 optionally isocyanate-reactive hydrogen compounds having an OH number of 140 mg KOH/g to 1800 mg KOH/g, A4 auxiliary and added-substance materials such as a) catalysts, b) surface-active added-substance materials, and c) pigments or flame retardants, a) catalysts, b) surface-active added-substance materials, and c) pigments or flame retardants, a mixture of di- and polyisocyanates of the diphenylmethane series, optionally one or more polyether polyols having a functionality of 2 to 8, preferably of 2 to 6, a DIN 53240 OH number of ≥ 9 mg KOH/g to ≤ 56 mg KOH/g, wherein the ratio of 4,4'-MDI to 2,4'-MDI is between 1.6 and 2.7 and total monomer content is 75 to 85 wt%, based on the sum total of isocyanates used,
A compound of Formula I, or a pharmaceutically acceptable salt, a hydrate or a solvate thereof, wherein: X=P, " " represents a single bond, R 1 and R 2 each are independently hydroxyl or C 1-6 alkoxy, said C 1-6 alkoxy is optionally substituted by 1-2 substituents independently selected from the group consisting of: aryl, amino, hydroxyl, cyano, nitro, C 1-4 alkyl and halogen (e.g., F, Cl, Br or I), said aryl is optionally substituted by 1-2 substituents independently selected from the group consisting of: aryl, amino, hydroxyl, cyano, nitro, C 1-4 alkyl and halogen (e.g., F, Cl, Br or I).
A computer implemented method for facilitating automatically adjusting an operational parameter within a heterogeneous mesh network (200, 830), the method being performed by a Self-Organizing Network, SON, module (240, 330, 820) and comprising the steps of: a. receiving an environmental condition for a heterogeneous mesh network (200, 830) from at least one of at least two multi-RAT base stations (210, 220, 230, 840, 850) in the heterogeneous mesh network (200, 830), the at least one of the at least two multi-RAT base stations (210, 220, 230, 840, 850) using a Wi-Fi radio for backhaul radio and a Long-Term Evolution, LTE, radio for access radio; b. storing the environmental condition in a memory; c. evaluating the environmental condition; d. determining that the at least one of the at least two multi-RAT base stations (210, 220, 230, 840, 850) is experiencing a backlog or is nearing a capacity threshold on the access radio, based on the environmental condition; and e. instructing the at least one of the at least two multi-RAT base stations (210, 220, 230, 840, 850) to switch the access radio to the backhaul radio and vice-versa, so that the LTE radio is used for backhaul radio and the Wi-Fi radio is used for access radio. a. receiving an environmental condition for a heterogeneous mesh network (200, 830) from at least one of at least two multi-RAT base stations (210, 220, 230, 840, 850) in the heterogeneous mesh network (200, 830), the at least one of the at least two multi-RAT base stations (210, 220, 230, 840, 850) using a Wi-Fi radio for backhaul radio and a Long-Term Evolution, LTE, radio for access radio; b. storing the environmental condition in a memory; c. evaluating the environmental condition; d. determining that the at least one of the at least two multi-RAT base stations (210, 220, 230, 840, 850) is experiencing a backlog or is nearing a capacity threshold on the access radio, based on the environmental condition; and e. instructing the at least one of the at least two multi-RAT base stations (210, 220, 230, 840, 850) to switch the access radio to the backhaul radio and vice-versa, so that the LTE radio is used for backhaul radio and the Wi-Fi radio is used for access radio.
A carotenoid-containing composition for use in the treatment of hyperlipidemia, obesity, hypertension, arteriosclerosis, diabetes, cardiac infarction or cerebral infarction, the carotenoid-containing composition including: a carotenoid component including lycopene, wherein at least 90% by mass of the lycopene is in a non-crystalline state; and diglyceryl monostearate. a carotenoid component including lycopene, wherein at least 90% by mass of the lycopene is in a non-crystalline state; and diglyceryl monostearate.
A photodynamic therapeutic or diagnostic agent comprising: a particle that emits upconversion luminescence by infrared-spectrum light; and a 5-aminolevulinic acid or derivative thereof or a salt of the 5-aminolevulinic acid or the derivative, wherein the ALA derivative is represented by the formula R 2 R 1 NCH 2 COCH 2 CH 2 COR 3, wherein R 1 and R 2 each independently represent a hydrogen atom, an alkyl group, an acyl group, an alkoxycarbonyl group, an aryl group, or an aralkyl group; and R 3 represents a hydroxy group, an alkoxy group, an acyloxy group, an alkoxycarbonyloxy group, an aryloxy group, an aralkyloxy group, or an amino group, provided that ALA wherein each of R 1 and R 2 is a hydrogen atom and R 3 is a hydroxy group is excluded.
An electrostatic discharge, ESD, protection circuit, the ESD protection circuit comprising: a first power supply for providing a first supply voltage, the first power supply being connected to a node through a first diode; a second power supply for providing a second supply voltage, the second power supply being connected to the node through a second diode; an inverter (118, 120) arranged to receive an input voltage from the node and produce an output voltage; an ESD discharge device arranged to receive the output voltage from the inverter (118, 120) and provide a discharge path for the first power supply and the second power supply if the output voltage indicates occurrence of an ESD event affecting the first power supply or the second power supply; and a resistor-capacitor, RC, circuit (112, 116) connected between the node and a system ground, the RC circuit (112, 116) operating as a trigger that causes the input voltage to indicate occurrence of the ESD event for the ESD discharge device to provide a discharge path for the first power supply and the second power supply. a first power supply for providing a first supply voltage, the first power supply being connected to a node through a first diode; a second power supply for providing a second supply voltage, the second power supply being connected to the node through a second diode; an inverter (118, 120) arranged to receive an input voltage from the node and produce an output voltage; an ESD discharge device arranged to receive the output voltage from the inverter (118, 120) and provide a discharge path for the first power supply and the second power supply if the output voltage indicates occurrence of an ESD event affecting the first power supply or the second power supply; and a resistor-capacitor, RC, circuit (112, 116) connected between the node and a system ground, the RC circuit (112, 116) operating as a trigger that causes the input voltage to indicate occurrence of the ESD event for the ESD discharge device to provide a discharge path for the first power supply and the second power supply.
Cartridge with a first opening, a second opening, a channel, which extends from the first opening to the second opening and has a taper, an intraocular lens, which is arranged in the channel between the first opening and the second opening, and a cartridge plunger, which is arranged in the channel between the intraocular lens and the second opening and is set up to first preload the intraocular lens by displacing the cartridge plunger toward the first opening, then to fold the intraocular lens by displacing it in the taper and then to push the lens out of the channel via the first opening, wherein the cartridge is set up to be coupled with a syringe, so that a fluid can be forced into the channel via the second opening by means of the syringe and the cartridge plunger can thereby be propelled in a direction of insertion toward the first opening, wherein the cartridge plunger has a first cartridge-plunger longitudinal end and a second cartridge-plunger longitudinal end, characterized in that the cartridge plunger has a fluid line, which extends from the first cartridge-plunger longitudinal end to the second cartridge-plunger longitudinal end and via which the fluid can be forced in from the second cartridge-plunger longitudinal end to the first cartridge-plunger longitudinal end and then to the intraocular lens.
A compound of formula III, or pharmaceutically acceptable salts thereof, wherein: R 1 is hydrogen or methyl; P is hydrogen or hydroxyl; M is H or a group such that CO 2 M is a carboxylic acid, a carboxylate anion, a pharmaceutically acceptable ester group, or a carboxylic acid protected by a protecting group selected from allyl, benzhydryl, 2-naphthylmethyl, benzyl (Bn), silyl, phenacyl, p- methoxybenzyl, o -nitrobenzyl, p -methoxyphenyl, p -nitrobenzyl, 4-pyridylmethyl and t-butyl; Y is -(CH 2) n -A, wherein n is 1-4 and A is -CN, -N(R 2) 2, C(=O)-N(R 2) 2, -C(=O)-NR 2 SO 2 N(R 2) 2, NR 2 SO 2 N(R 2) 2, NH-C(=NR 2)-N(R 2) 2, -S-C(=NR 2)-N(R 2) 2, wherein each R 2 is independently H or C 1 -C 4 alkyl; and wherein alkyl is a saturated straight, branched, or if appropriate, cyclic alkyl group, including both substituted and unsubstituted forms; moieties with which the alkyl group can be substituted are selected from the group consisting of hydroxyl, halo (F, Cl, Br, I), amino, alkylamino, arylamino, alkoxy, aryloxy, nitro, cyano, sulfonic acid, sulfate, phosphonic acid, phosphate, or phosphonate; wherein the aryl group can be substituted with one or more moieties selected from the group consisting of bromo, chloro, fluoro, iodo, hydroxyl, amino, alkylamino, arylamino, alkoxy, aryloxy, nitro, cyano, sulfonic acid, sulfate, phosphonic acid, phosphate, or phosphonate; wherein the alkoxy group is C 1 -C 4 alkyl-O-, with the alkyl group optionally substitued as described above. R 1 is hydrogen or methyl; P is hydrogen or hydroxyl; M is H or a group such that CO 2 M is a carboxylic acid, a carboxylate anion, a pharmaceutically acceptable ester group, or a carboxylic acid protected by a protecting group selected from allyl, benzhydryl, 2-naphthylmethyl, benzyl (Bn), silyl, phenacyl, p- methoxybenzyl, o -nitrobenzyl, p -methoxyphenyl, p -nitrobenzyl, 4-pyridylmethyl and t-butyl; Y is -(CH 2) n -A, wherein n is 1-4 and A is -CN, -N(R 2) 2, C(=O)-N(R 2) 2, -C(=O)-NR 2 SO 2 N(R 2) 2, NR 2 SO 2 N(R 2) 2, NH-C(=NR 2)-N(R 2) 2, -S-C(=NR 2)-N(R 2) 2, wherein each R 2 is independently H or C 1 -C 4 alkyl; and wherein alkyl is a saturated straight, branched, or if appropriate, cyclic alkyl group, including both substituted and unsubstituted forms; moieties with which the alkyl group can be substituted are selected from the group consisting of hydroxyl, halo (F, Cl, Br, I), amino, alkylamino, arylamino, alkoxy, aryloxy, nitro, cyano, sulfonic acid, sulfate, phosphonic acid, phosphate, or phosphonate; wherein the aryl group can be substituted with one or more moieties selected from the group consisting of bromo, chloro, fluoro, iodo, hydroxyl, amino, alkylamino, arylamino, alkoxy, aryloxy, nitro, cyano, sulfonic acid, sulfate, phosphonic acid, phosphate, or phosphonate; wherein the alkoxy group is C 1 -C 4 alkyl-O-, with the alkyl group optionally substitued as described above.
A seat for supporting an occupant of a vehicle, said seat comprising: a seating frame member for providing a surface to support the occupant; a back frame member extending away from said seating frame member; and a bracket coupled to both said seating frame member and said back frame member with said bracket having a periphery and having a central longitudinal axis dividing said bracket into a front portion and a rear portion; wherein said front portion of said bracket defines a yield segment for plastically deforming when a force above a predetermined value is applied to said back frame member to reduce an impact force transferred from said seat to the occupant caused by the force above the predetermined value, and wherein said periphery of said rear portion of said bracket includes a first contact surface and a second contact surface spaced from said first contact surface to define a bracket notch whereby said first contact surface moves into contact with said second contact surface as said yield segment plastically deforms thereby restricting the plastic deformation of said yield segment, characterized in that said front portion of said bracket defines at least one void for allowing said yield segment to plastically deform with said yield segment disposed between said void and said periphery of said bracket. a seating frame member for providing a surface to support the occupant; a back frame member extending away from said seating frame member; and a bracket coupled to both said seating frame member and said back frame member with said bracket having a periphery and having a central longitudinal axis dividing said bracket into a front portion and a rear portion; wherein said front portion of said bracket defines a yield segment for plastically deforming when a force above a predetermined value is applied to said back frame member to reduce an impact force transferred from said seat to the occupant caused by the force above the predetermined value, and wherein said periphery of said rear portion of said bracket includes a first contact surface and a second contact surface spaced from said first contact surface to define a bracket notch whereby said first contact surface moves into contact with said second contact surface as said yield segment plastically deforms thereby restricting the plastic deformation of said yield segment, characterized in that said front portion of said bracket defines at least one void for allowing said yield segment to plastically deform with said yield segment disposed between said void and said periphery of said bracket.
A dual polarization multi-band antenna, comprising: a waveguide including a high band feed section, a transition section, a low band feed section and a quad ridged waveguide horn coupled in series; wherein the high band feed section is configured to support propagation of electromagnetic waves in a high wavelength band and to not support propagation of electromagnetic waves in a low wavelength band; the transition section is configured to couple electromagnetic waves in the high band from the high band feed section to the low band feed section, and to inhibit backward propagation of electromagnetic waves in the low band; the low band feed section is configured to support propagation of electromagnetic waves in the low wavelength band and the high wavelength band, wherein the low band feed section comprises a quad ridged waveguide, and a horizontal low band feed (244/246/248) and a vertical low band feed (234/236/238) to couple forward-propagating orthogonally polarized low band electromagnetic waves into the quad ridged waveguide; and wherein the horn is configured to couple electromagnetic waves in the low wavelength band and the high wavelength band from the low band feed section into free space. a waveguide including a high band feed section, a transition section, a low band feed section and a quad ridged waveguide horn coupled in series; wherein the high band feed section is configured to support propagation of electromagnetic waves in a high wavelength band and to not support propagation of electromagnetic waves in a low wavelength band; the transition section is configured to couple electromagnetic waves in the high band from the high band feed section to the low band feed section, and to inhibit backward propagation of electromagnetic waves in the low band; the low band feed section is configured to support propagation of electromagnetic waves in the low wavelength band and the high wavelength band, wherein the low band feed section comprises a quad ridged waveguide, and a horizontal low band feed (244/246/248) and a vertical low band feed (234/236/238) to couple forward-propagating orthogonally polarized low band electromagnetic waves into the quad ridged waveguide; and wherein the horn is configured to couple electromagnetic waves in the low wavelength band and the high wavelength band from the low band feed section into free space.
A dermal composition suitable for use in treating a patient, wherein the composition comprises a nanoparticle surface-functionalized with an oligonucleotide, wherein the density of oligonucleotide on the surface of the nanoparticle is at least 2 pmol/cm 2, and the use comprises: administering a therapeutically effective amount of the composition and a dermal vehicle to the skin of the patient under conditions wherein the nanoparticle surface-functionalized with the oligonucleotide hybridizes to a target and regulates expression of a target polypeptide.
A tornado yoyo, comprising two rotating disks and a connecting axle configured to connect back portions of the two rotating disks, wherein, a protruding cylinder provided with a bearing thereon is disposed within each rotating disk and located in the middle of each rotating disk; a rotating cap is disposed outside each rotating disk and provided with a connecting hole portion extending from the middle of the rotating cap to the rotating disk, and the connecting hole portion is sleeved on the bearing to realize a rotation of the rotating cap relative to the rotating disk; and an outer edge of each rotating cap is provided with an edgefold configured to envelop an edge of the rotating disk; characterized in that each end of the protruding cylinder is provided with a screw hole, and after the bearing is sleeved on the protruding cylinder, a screw is screwed into the screw hole to realize a connection between the bearing and the protruding cylinder, in which the screw has a head whose diameter is larger than that of the protruding cylinder.
An apparatus, comprising: an illumination source (102, 200, 300, 400) configured to produce and direct a multi-wavelength illumination beam (104, 204, 304, 602, 702, 806a-806c) to a microfluidic target (106, 208, 308, 412, 504, 604, 704, 802) that can include nanotags (112a, 112b); a detector (118, 622a-622d, 638, 724) configured to receive a multi-wavelength detection beam (120, 140, 502, 620, 634, 720, 808a-808c) from the microfluidic target (106, 208, 308, 412, 504, 604, 704, 802) and to produce a detection signal, wherein the multi-wavelength detection beam (120, 140, 502, 620, 634, 720, 808a-808c) comprises light that is elastically side-scattered by an interaction between the multi-wavelength illumination beam (104, 204, 304, 602, 702, 806a-806c) and the nanotags (112a, 112b) in the microfluidic target (106, 208, 308, 412, 504, 604, 704, 802); and a processor configured to receive the detection signal and to determine the presence of the nanotags (112a, 112b) in the microfluidic target (106, 208, 308, 412, 504, 604, 704, 802) by comparing multiple wavelength side-scatter intensity characteristics of the detection signal with predetermined multi-wavelength elastic side-scatter intensity profiles of one or more nanotag (112a, 112b) types. an illumination source (102, 200, 300, 400) configured to produce and direct a multi-wavelength illumination beam (104, 204, 304, 602, 702, 806a-806c) to a microfluidic target (106, 208, 308, 412, 504, 604, 704, 802) that can include nanotags (112a, 112b); a detector (118, 622a-622d, 638, 724) configured to receive a multi-wavelength detection beam (120, 140, 502, 620, 634, 720, 808a-808c) from the microfluidic target (106, 208, 308, 412, 504, 604, 704, 802) and to produce a detection signal, wherein the multi-wavelength detection beam (120, 140, 502, 620, 634, 720, 808a-808c) comprises light that is elastically side-scattered by an interaction between the multi-wavelength illumination beam (104, 204, 304, 602, 702, 806a-806c) and the nanotags (112a, 112b) in the microfluidic target (106, 208, 308, 412, 504, 604, 704, 802); and a processor configured to receive the detection signal and to determine the presence of the nanotags (112a, 112b) in the microfluidic target (106, 208, 308, 412, 504, 604, 704, 802) by comparing multiple wavelength side-scatter intensity characteristics of the detection signal with predetermined multi-wavelength elastic side-scatter intensity profiles of one or more nanotag (112a, 112b) types.
A composition comprising a dose of between 0.2 and 0.6 mg of colchicine and/or a salt thereof, for use in treating and/or preventing a cardiovascular event in a subject, wherein the composition is to be administered once per day and the cardiovascular event is acute coronary syndrome, out-of-hospital cardiac arrest, or noncardioembolic ischemic stroke.
A polynucleotide sequence comprising a nucleic acid sequence according to SEQ ID NO: 1; or a nucleic acid sequence with at least 97% sequence identity with the nucleic acid of SEQ ID NO: 1..
An aqueous oxidizer solution consisting of a mixture of dissolved oxidizing nitrate salts and water, for use in the preparation of explosives formulations, which has a crystallization point of 10°C or less; said solution consisting of: between 12% and 24% by mass water; an alkylamine nitrate or monoethanolamine nitrate in an amount of 10% to 18% by mass; and ammonium nitrate and calcium nitrate or mixture of calcium nitrate and magnesium nitrate; wherein the molar concentration of ammonium nitrate to calcium nitrate or mixture of calcium nitrate and magnesium nitrate is between 0.75:1 and 1.25:1. between 12% and 24% by mass water; an alkylamine nitrate or monoethanolamine nitrate in an amount of 10% to 18% by mass; and ammonium nitrate and calcium nitrate or mixture of calcium nitrate and magnesium nitrate; wherein the molar concentration of ammonium nitrate to calcium nitrate or mixture of calcium nitrate and magnesium nitrate is between 0.75:1 and 1.25:1.
A pharmaceutical composition for use in preventing and treating thrombotic disorders, comprising an extract of leaves of Lindera obtusiloba as an active ingredient, wherein the thrombotic disorder is selected from the group of atherothrombotic diseases, phlebothrombosis, hepatic portal vein thrombosis, pulmonary thromboembolism, chronic limb ischemia, varicose vein, deep vein thrombosis diseases, cerebral infarction, and cerebral hemorrhage.